ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Roivant Sciences Ltd

Roivant Sciences Ltd (ROIV)

11,16
-0,11
(-0,98%)
Geschlossen 23 Januar 10:00PM
11,16
0,00
( 0,00% )
Vor Marktöffnung: 10:03AM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
11,16
Gebot
11,05
Fragen
12,39
Volumen
-
0,00 Tagesbereich 0,00
9,69 52-Wochen-Bereich 13,055
Marktkapitalisierung
Handelsende
11,16
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
4.858.879
Ausgegebene Aktien
727.949.744
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
1,87
Gewinn pro Aktie (EPS)
5,97
Erlöse
124,8M
Nettogewinn
4,35B

Über Roivant Sciences Ltd

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Hamilton, Bmu
Gegründet
-
Roivant Sciences Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ROIV. The last closing price for Roivant Sciences was US$11,16. Over the last year, Roivant Sciences shares have traded in a share price range of US$ 9,69 to US$ 13,055.

Roivant Sciences currently has 727.949.744 shares in issue. The market capitalisation of Roivant Sciences is US$8,12 billion. Roivant Sciences has a price to earnings ratio (PE ratio) of 1.87.

ROIV Neueste Nachrichten

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and...

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and...

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their...

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed...

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability...

Roivant Provides Update on Graves’ Disease Development Program

High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on...

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2024, and provided...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.040.35971223021611.1211.3810.89388090311.12237707CS
4-0.82-6.8447412353911.9812.210.42441722011.27874387CS
12-0.56-4.7781569965911.7212.93510.42485887911.73101868CS
260.060.54054054054111.113.05510.04532348411.68633187CS
520.858.244422890410.3113.0559.69572003411.2316905CS
1564.0657.18309859157.113.242.52383044510.16095252CS
2601.6617.47368421059.516.762.52353820710.14301936CS

ROIV - Frequently Asked Questions (FAQ)

What is the current Roivant Sciences share price?
The current share price of Roivant Sciences is US$ 11,16
How many Roivant Sciences shares are in issue?
Roivant Sciences has 727.949.744 shares in issue
What is the market cap of Roivant Sciences?
The market capitalisation of Roivant Sciences is USD 8,12B
What is the 1 year trading range for Roivant Sciences share price?
Roivant Sciences has traded in the range of US$ 9,69 to US$ 13,055 during the past year
What is the PE ratio of Roivant Sciences?
The price to earnings ratio of Roivant Sciences is 1,87
What is the cash to sales ratio of Roivant Sciences?
The cash to sales ratio of Roivant Sciences is 65,11
What is the reporting currency for Roivant Sciences?
Roivant Sciences reports financial results in USD
What is the latest annual turnover for Roivant Sciences?
The latest annual turnover of Roivant Sciences is USD 124,8M
What is the latest annual profit for Roivant Sciences?
The latest annual profit of Roivant Sciences is USD 4,35B
What is the registered address of Roivant Sciences?
The registered address for Roivant Sciences is CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON, D0 HM11
What is the Roivant Sciences website address?
The website address for Roivant Sciences is www.roivant.com
Which industry sector does Roivant Sciences operate in?
Roivant Sciences operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
DGNXDiginex Ltd
 14,18
(89,07%)
485,97k
FSEAFirst Seacoast Bancorp Inc
US$ 15,90
(59,00%)
6
BKHABlack Hawk Acquisition Corporation
US$ 16,55
(58,98%)
9
BBGIBeasley Broadcast Group Inc
US$ 13,31
(58,45%)
14
CRWSCrown Crafts Inc
US$ 6,99
(56,03%)
1
VIRCVirco Manufacturing Company
US$ 6,01
(-45,86%)
70
CPBICentral Plains Bancshares Inc
US$ 10,01
(-31,67%)
7
DCOMDime Community Bancshares Inc
US$ 22,00
(-30,71%)
310
TSBKTimberland Bancorp Inc
US$ 21,01
(-27,63%)
12
XNCRXencor Inc
US$ 15,01
(-27,38%)
16
KOPNKopin Corporation
US$ 1,96
(33,33%)
12,72M
HEPAHepion Pharmaceuticals Inc
US$ 0,1504
(11,41%)
7,15M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,3038
(-4,76%)
5,79M
ASSTAsset Entities Inc
US$ 1,58
(16,18%)
4,66M
SHViShares Short Treasury Bond ETF
US$ 110,37
(0,01%)
3,42M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock